Minor plasma lipids modulate clotting factor activities and may affect thrombosis risk
| Autor: | Darlene J. Elias, John H. Griffin, Hiroshi Deguchi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty 030204 cardiovascular system & hematology Biology Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Thrombin Internal medicine medicine Clotting factor Sphingosine Lipid metabolism Hematology Lipidome medicine.disease Sphingolipid Venous thrombosis 030104 developmental biology Endocrinology Coagulation chemistry Immunology lipids (amino acids peptides and proteins) medicine.drug |
| Zdroj: | Research and Practice in Thrombosis and Haemostasis. 1:93-102 |
| ISSN: | 2475-0379 |
| Popis: | Different minor abundance plasma lipids significantly influence thrombin generation in vitro and significant differences in such lipids are linked to risk for venous thrombosis. Some plasma sphingolipids including glucosylceramide, lyso-sulfatide and sphingosine have anticoagulant properties whereas, conversely, some plasma phospholipid derivatives, including certain lyso-phospholipids and ethanolamides, have procoagulant properties. Plasma metabolite profiling of venous thrombosis patients showed association of venous thrombosis with decreased plasma long-chain acylcarntines, leading to discovery of their anticoagulant activity as inhibitors of factor Xa. Inhibition of factor Xa by acylcarnitines does not require the protein’s Gla-domain, emphasizing an expanded framework for the paradigm for lipid-clotting factor interactions. Overall, whether by genetics or environment, alterations in the dynamics of lipid metabolism linked to an altered lipidome may contribute to regulation of blood coagulation because imbalances between physiologic procoagulant and anticoagulant lipids may contribute to excessive thrombin generation that augments risk for thrombosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text